Difference between revisions of "Non-small cell lung cancer, RET-positive"
Jump to navigation
Jump to search
m |
|||
| Line 31: | Line 31: | ||
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
| − | |[https:// | + | |[https://doi.org/10.1056/nejmoa2005653 Drilon et al. 2020 (LIBRETTO-001)] |
| style="background-color:#91cf61" |Phase I/II (RT) | | style="background-color:#91cf61" |Phase I/II (RT) | ||
|- | |- | ||
| Line 47: | Line 47: | ||
===References=== | ===References=== | ||
| − | #'''Abstract.''' Drilon, A., Oxnard, G., Wirth, L., Besse, B., Gautschi, O., Tan, S.W.D., Loong, H., Bauer, T., Kim, Y.J., Horiike, A., Park, K., Shah, M., McCoach, C., Bazhenova, L., Seto, T., Brose, M., Pennell, N., Weiss, J., Matos, I., Peled, N., Cho, B.C., Ohe, Y., Reckamp, K., Boni, V., Satouchi, M., Falchook, G., Akerley, W., Daga, H., Sakamoto, T., Patel, J., Lakhani, N., Barlesi, F., Burkard, M., Zhu, V., Moreno Garcia, V., Medioni, J., Matrana, M., Rolfo, C., Lee, D.H., Nechushtan, H., Johnson, M., Velcheti, V., Nishio, M., Toyozawa, R., Ohashi, K., Song, L., Han, J., Spira, A., De Braud, F., Staal Rohrberg, K., Takeuchi, S., Sakakibara, J., Waqar, S., Kenmotsu, H., Wilson, F., B.Nair, Olek, E., Kherani, J., Ebata, K., Zhu, E., Nguyen, M., Yang, L., Huang, X., Cruickshank, S., Rothenberg, S., Solomon, B., Goto, K., Subbiah, V. PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers. [https://www.jto.org/article/S1556-0864(19)30742-7/fulltext link to abstract] | + | <!-- #'''Abstract.''' Drilon, A., Oxnard, G., Wirth, L., Besse, B., Gautschi, O., Tan, S.W.D., Loong, H., Bauer, T., Kim, Y.J., Horiike, A., Park, K., Shah, M., McCoach, C., Bazhenova, L., Seto, T., Brose, M., Pennell, N., Weiss, J., Matos, I., Peled, N., Cho, B.C., Ohe, Y., Reckamp, K., Boni, V., Satouchi, M., Falchook, G., Akerley, W., Daga, H., Sakamoto, T., Patel, J., Lakhani, N., Barlesi, F., Burkard, M., Zhu, V., Moreno Garcia, V., Medioni, J., Matrana, M., Rolfo, C., Lee, D.H., Nechushtan, H., Johnson, M., Velcheti, V., Nishio, M., Toyozawa, R., Ohashi, K., Song, L., Han, J., Spira, A., De Braud, F., Staal Rohrberg, K., Takeuchi, S., Sakakibara, J., Waqar, S., Kenmotsu, H., Wilson, F., B.Nair, Olek, E., Kherani, J., Ebata, K., Zhu, E., Nguyen, M., Yang, L., Huang, X., Cruickshank, S., Rothenberg, S., Solomon, B., Goto, K., Subbiah, V. PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers. [https://www.jto.org/article/S1556-0864(19)30742-7/fulltext link to abstract] --> |
| + | # '''LIBRETTO-001:''' Drilon A, Oxnard GR, Tan DSW, Loong HHF, Johnson M, Gainor J, McCoach CE, Gautschi O, Besse B, Cho BC, Peled N, Weiss J, Kim YJ, Ohe Y, Nishio M, Park K, Patel J, Seto T, Sakamoto T, Rosen E, Shah MH, Barlesi F, Cassier PA, Bazhenova L, De Braud F, Garralda E, Velcheti V, Satouchi M, Ohashi K, Pennell NA, Reckamp KL, Dy GK, Wolf J, Solomon B, Falchook G, Ebata K, Nguyen M, Nair B, Zhu EY, Yang L, Huang X, Olek E, Rothenberg SM, Goto K, Subbiah V. Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2020 Aug 27;383(9):813-824. [https://doi.org/10.1056/nejmoa2005653 link to original article] [https://pubmed.ncbi.nlm.nih.gov/32846060 PubMed] | ||
[[Category:Non-small cell lung cancer medications]] | [[Category:Non-small cell lung cancer medications]] | ||
[[Category:Biomarker-specific pages]] | [[Category:Biomarker-specific pages]] | ||
[[Category:Lung cancers]] | [[Category:Lung cancers]] | ||
Revision as of 23:52, 28 August 2020
| Page editor | Section editor | ||
|---|---|---|---|
 |
Amit Kulkarni, MBBS University of Minnesota Minneapolis, MN  AmitKulkarniMD
|
 |
Travis Osterman, DO, MS Vanderbilt University Nashville, TN TravisOsterman |
Note: these are regimens tested in biomarker-specific populations, please see the main NSCLC page for other regimens.
7 regimens on this page
7 variants on this page
|
Advanced or metastatic disease
Selpercatinib monotherapy
| back to top |
Regimen
| FDA-recommended dose |
| Study | Evidence |
|---|---|
| Drilon et al. 2020 (LIBRETTO-001) | Phase I/II (RT) |
Biomarker eligibility criteria
- RET fusion positive
Chemotherapy
- Selpercatinib (Retevmo) with or without food, as follows:
- Less than 50 kg: 120 mg PO twice per day
- 50 kg or more: 160 mg PO twice per day
Continued indefinitely
References
- LIBRETTO-001: Drilon A, Oxnard GR, Tan DSW, Loong HHF, Johnson M, Gainor J, McCoach CE, Gautschi O, Besse B, Cho BC, Peled N, Weiss J, Kim YJ, Ohe Y, Nishio M, Park K, Patel J, Seto T, Sakamoto T, Rosen E, Shah MH, Barlesi F, Cassier PA, Bazhenova L, De Braud F, Garralda E, Velcheti V, Satouchi M, Ohashi K, Pennell NA, Reckamp KL, Dy GK, Wolf J, Solomon B, Falchook G, Ebata K, Nguyen M, Nair B, Zhu EY, Yang L, Huang X, Olek E, Rothenberg SM, Goto K, Subbiah V. Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2020 Aug 27;383(9):813-824. link to original article PubMed